CER Daily Newsfeed

Real World Data and Patient Planning Can Keep Trials from Collapsing

(12/4, Joshua Silverwood, GlobalData) reports “The judicious use of real-world data (RWD) could keep a Phase I or II trial from collapsing with the market for oncology treatments for indications non-small cell carcinoma (NSCLC) expected to grow by more than 40% by the end of the decade, bringing competition and opportunity to some markets.” Full

Prior Authorization Delays Cause Serious Harm to Patients With Cancer

(12/4, Pearl Steinzor, The American Journal of Managed Care) reports “...Prior authorization delays significantly harm cancer patients, causing treatment postponements, hospitalizations, and deaths, with 92% of oncologists reporting delays and 7% noting patient deaths. The burden of prior authorization has worsened, with 85% of oncologists reporting increased challenges, leading to staff burnout and inefficiencies in managing the process.” Full

Why Historical Data Will Be Important Under The New EU HTA Regulation

(12/4, Eliza Slawther, Pink Sheet) reports “...The EU Health Technology Assessment (HTA) regulation, which will begin to apply from January 2025, will see companies further utilize historical data to demonstrate the clinical impact of their product, said Christian Schneider, of the pharmaceutical services provider, Cencora, and a former chair of the European Medicines Agency’s Committee for Advanced Therapies (CAT).” Subscription Required

Canadian HTA Agency Consults On First Methods Guideline

(12/4, Francesca Bruce, Pink Sheet) reports “...Canada’s Drug Agency (CDA), the national health technology assessment body, is seeking feedback on its first ever methods guide in a bid to improve transparency and understanding of its work, and to explain the types of evidence that can help show a product’s comparative effectiveness.” Subscription Required